What is NDC 70710-1848?

70710-1848 is the product NDC for Fluvoxamine maleate extended-release, Fluvoxamine maleate 150 mg/1 capsule, extended release, listed with the FDA by Zydus Pharmaceuticals USA Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

Zydus Pharmaceuticals USA Inc., NDC labeler code 70710. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Fluvoxamine maleate extended-release?

3 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Fluvoxamine maleate extended-release NDC 70710-1848

NDC codes

FDA NDC Directory

Product NDC (as listed)70710-1848Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70710-1848Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70710-1848-3	7071018480370710184803	30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (70710-1848-3)Marketed from Aug 4, 2026

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Fluvoxamine maleate extended-release
Generic name (nonproprietary): fluvoxamine maleate extended-release
Active ingredients: Fluvoxamine maleate — 150 mg/1
Dosage form: Capsule, Extended release
Route: Oral
Labeler: Zydus Pharmaceuticals USA Inc.NDC labeler code 70710
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 220447
Marketing start: Aug 4, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Serotonin Uptake Inhibitors (Mechanism)
Identifiers: Product ID 70710-1848_cba28687-9ade-400c-9d15-c7de1d2113beSPL ID cba28687-9ade-400c-9d15-c7de1d2113beSPL set ID 6c71d4f6-54b5-4d3a-8d2f-b7773c92c32eRxCUI 903873, 903879UNII 5LGN83G74V
Pharmacologic class: Serotonin Reuptake Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470710184803 followed by a unit qualifier and the quantity

Package 70710-1848-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 27, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Fluvoxamine maleate extended-release capsules are a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of obsessive compulsive disorder (OCD) ( 1 ). Efficacy was demonstrated in: One 12-week study with fluvoxamine maleate extended-release capsules in adults ( 14.1 ) . Two 10-week studies with immediate-release (IR) fluvoxamine tablets in adults and one 10-week study with IR fluvoxamine tablets in children and adolescents ( 14.1 , 14.3 ) . One maintenance study with IR fluvoxamine tablets ( 14.2 ) . 1.1 Obsessive Compulsive Disorder Fluvoxamine maleate extended-release capsules are indicated for the treatment of obsessive compulsive disorder (OCD), as defined in the DSM…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 70710-1848

What is NDC 70710-1848?: 70710-1848 is the product NDC for Fluvoxamine maleate extended-release, Fluvoxamine maleate 150 mg/1 capsule, extended release, listed with the FDA by Zydus Pharmaceuticals USA Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Fluvoxamine maleate extended-release.
What is the active ingredient?: Fluvoxamine maleate.
Who is the labeler?: Zydus Pharmaceuticals USA Inc., NDC labeler code 70710. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Fluvoxamine maleate extended-release?: 3 other product NDCs are listed under this name. See all Fluvoxamine maleate extended-release NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Fluvoxamine maleate extended-release NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Fluvoxamine maleate extended-release	Fluvoxamine maleate 100 mg/1	Capsule, Extended releaseOral	Zydus Pharmaceuticals USA Inc.	70710-1847	70710-1847-03
Fluvoxamine maleate extended-release	Fluvoxamine maleate 100 mg/1	Capsule, Extended releaseOral	Zydus Lifesciences Limited	70771-1957	70771-1957-03
Fluvoxamine maleate extended-release	Fluvoxamine maleate 150 mg/1	Capsule, Extended releaseOral	Zydus Lifesciences Limited	70771-1958	70771-1958-03

Other NDCs under ANDA 220447

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 220447
Product	Strength	Form · route	Labeler	Product NDC
Fluvoxamine maleate extended-release	Fluvoxamine maleate 100 mg/1	Capsule, Extended releaseOral	Zydus Pharmaceuticals USA Inc.	70710-1847
Fluvoxamine maleate extended-release	Fluvoxamine maleate 100 mg/1	Capsule, Extended releaseOral	Zydus Lifesciences Limited	70771-1957
Fluvoxamine maleate extended-release	Fluvoxamine maleate 150 mg/1	Capsule, Extended releaseOral	Zydus Lifesciences Limited	70771-1958